Building indigenous DIAGNOSTIC CAPABILITIES
Bio Spectrum|June 2020
India is facing a bigger burden of not having enough diagnostic kits in hand. Specifically, there is a shortage of reagents and consumables required to carry out the diagnostic tests for COVID-19. In order to overcome this burden, India is reaching out to South Korea, USA, Germany and China to arrange for more kits in order to increase the current testing capacity for COVID-19. Although this step might help India to some extent in its current containment plan, the real need can only be fulfilled by accelerating indigenous COVID-19 diagnostics manufacturing.
Dr Manbeena Chawla
Building indigenous DIAGNOSTIC CAPABILITIES

Accurate diagnosis of coronavirus infection is a very crucial tool to help identify and control the disease. During the ongoing COVID-19 pandemic, there is a lot of buzz regarding the possible errors in diagnoses with both reverse transcription-polymerase chain reaction (RT-PCR) tests and the faster antibody-based tests, all over the world.

RT-PCR testing, which is considered the gold standard for diagnosis of COVID-19, is vital, but it cannot always identify asymptomatic infections or infections in people who may have now recovered. This is where probably antibody tests can help because they look for antibodies even when an individual does not display the symptoms of the infection or has already recovered. But a low accuracy from these tests could diminish their usefulness as a catch-all screening tool.

Adding to this challenge, India is facing a bigger burden of not having enough diagnostic kits in hand. Specifically, there is a shortage of reagents, consumables and equipment required to carry out the diagnostic tests for COVID-19. Expressing his concerns, Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AIMED), New Delhi says, “Our main issue is immediate access of positive covid serum samples to in vitro diagnostic (IVD) manufacturers. Without this, no company can produce a reliable rapid test for COVID-19.”

In order to overcome such issues, India is reaching out to South Korea, USA, Germany and China to arrange for more kits in order to increase the current testing capacity for COVID-19. Although this step might help India to some extent in its current containment plan, the real need can only be fulfilled by accelerating indigenous COVID-19 diagnostics manufacturing.

Denne historien er fra June 2020-utgaven av Bio Spectrum.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra June 2020-utgaven av Bio Spectrum.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIO SPECTRUMSe alt
Economic Survey Lays Focus On Mental Healthcare For The First Time
Bio Spectrum

Economic Survey Lays Focus On Mental Healthcare For The First Time

For the first time ever, the Economic Survey 2023-24 tabled by the Union Minister of Finance and Corporate Affairs Nirmala Sitharaman in Parliament recently, talks extensively about mental health, its significance and implications on policy recommendations.

time-read
1 min  |
September 2024
IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus
Bio Spectrum

IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus

Indian Institute of Technology Guwahati (IIT-G) researchers have investigated the biochemistry of the African Swine Fever Virus (ASFV) protein, focusing on understanding the biochemical processes of infection to devise effective control strategies.

time-read
1 min  |
September 2024
13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors
Bio Spectrum

13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors

The 13th edition of Bengaluru INDIA NANO 2024, organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS), and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) concluded on August 3 with participation of 1018 delegates, 11 countries including Korea, Morocco, USA, UK, France, Canada, Germany, Netherlands, Russia, Japan, and Poland, 49 exhibitors comprising 21 startups and 28 industry and institutes, and 200 posters. The exhibition had a footfall of 3,000+ visitors.

time-read
3 mins  |
September 2024
Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle
Bio Spectrum

Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle

The news has been around for a while which has put a big question mark ahead of the Indian nutraceuticals industry.

time-read
9 mins  |
September 2024
Can India Reclaim API Throne from China?
Bio Spectrum

Can India Reclaim API Throne from China?

Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).

time-read
10+ mins  |
September 2024
JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana
Bio Spectrum

JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana

JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax, has commissioned a new manufacturing facility for cotton-based croscarmellose sodium.

time-read
1 min  |
September 2024
NovaLead's patented repurposed drug for treating DFU gets CDSCO approval
Bio Spectrum

NovaLead's patented repurposed drug for treating DFU gets CDSCO approval

Pune-based NovaLead Pharma has announced that the drug regulator in India, Central Drugs Standard Control Organisation (CDSCO), has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.

time-read
1 min  |
September 2024
Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda
Bio Spectrum

Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda

Delhi-based pharma company Medicamen Organics has taken a significant step in its global expansion strategy by signing a Memorandum of Understanding (MoU) with Depot Pharmacy Yego in Rwanda.

time-read
1 min  |
September 2024
Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr
Bio Spectrum

Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr

Mankind Pharma has entered into a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines Limited (BSV) from Advent International, for an enterprise value of approx.

time-read
1 min  |
September 2024
Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence
Bio Spectrum

Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence

Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business.

time-read
1 min  |
September 2024